Physician profile
Jared Marshall
NPI 1265880918
$8,043.58
in general payments reported to CMS, 2019-2025
29 companies · $1,901 in 2025
The $1,901 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $230 · 2022: $1,104 · 2023: $2,059 · 2024: $2,750 · 2025: $1,901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,585 · Education: $106 · Travel and Lodging: $19.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,585.03 |
| Education | $105.74 |
| Travel and Lodging | $19.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $910.00 | 2021-2025 | Jardiance |
| Amgen INC. | $807.81 | 2021-2025 | Repatha, Repatha |
| Intuitive Surgical, INC. | $713.86 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $629.91 | 2022-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $530.19 | 2022-2025 | |
| Pfizer INC. | $481.03 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $471.81 | 2022-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $372.78 | 2022-2025 | Verquvo, Capvaxive |
| Alnylam Pharmaceuticals INC. | $334.15 | 2022-2025 | Onpattro |
| Abbott Laboratories | $309.53 | 2021-2025 | Jot Dx, Cardiomems |
| Actelion Pharmaceuticals US, INC. | $286.71 | 2024-2025 | Opsumit, Uptravi |
| Novo Nordisk INC | $285.86 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lexicon Pharmaceuticals, INC. | $282.69 | 2023-2024 | Inpefa |
| Boston Scientific Corporation | $267.41 | 2022-2023 | Watchman Access System |
| Kiniksa Pharmaceuticals International, Plc | $203.24 | 2024 | Arcalyst |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $197.25 | 2023-2025 | Farxiga, Wainua |
| Bayer Healthcare Pharmaceuticals INC. | $197.10 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $133.70 | 2022-2023 | |
| Lilly USA, LLC | $103.95 | 2023-2025 | Mounjaro, Zepbound |
| Esperion Therapeutics, INC. | $90.55 | 2025 | Nexletol |
| Daiichi Sankyo INC. | $74.07 | 2023-2024 | Injectafer |
| Kiniksa Pharmaceuticals, LTD. | $70.37 | 2022-2023 | Arcalyst |
| Bridgebio Pharma, INC. | $58.67 | 2025 | Attruby |
| Impulse Dynamics (USA) INC. | $55.96 | 2023-2024 | Optimizer, Optimizer |
| Tactile Systems Technology INC | $50.63 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Baxter Healthcare | $45.81 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Heartflow, INC. | $39.04 | 2025 | |
| Angiodynamics, INC. | $24.86 | 2024 | Auryon Laser System 100-120 Vac |
| Lantheus Medical Imaging, INC. | $14.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.